David M. Johnson

A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia

Susan O’Brien, Nicole Lamanna, Thomas J. Kipps et al. · Blood · 2015 · 239 citations · Full text

Localization of position within a homogeneous behavior chain: Effects of error contingencies

John R. Platt, David M. Johnson · Learning and Motivation · 1971 · 220 citations

Cognitive Science, Behavioral Sciences, Homogeneous Behavior Chain +10

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma

Ian W. Flinn, Brad S. Kahl, John P. Leonard et al. · Blood · 2014 · 206 citations · Full text

In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones

Ronald N. Jones, David M. Johnson, M E Erwin · Antimicrobial Agents and Chemotherapy · 1996 · 127 citations · Full text

Bioorganic Chemistry, Antimicrobial Chemotherapy, Antibiotic Resistance +23

Progression and Recapitulation of the Chondrocyte Differentiation Program: Cartilage Matrix Protein Is a Marker for Cartilage Maturation

Qian Chen, David M. Johnson, Dominik R. Haudenschild et al. · Developmental Biology · 1995 · 117 citations

Musculoskeletal Research, Developmental Biology, Cartilage Matrix Biology +12